Journal
TRENDS IN CELL BIOLOGY
Volume 29, Issue 10, Pages 777-790Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcb.2019.07.002
Keywords
-
Categories
Funding
- INSERM
- Universite de Toulouse 3
- CNRS
- Roche (imCORE)
- Ligue Contre Le Cancer
- Canceropole Grand Sud-Ouest
- Fondation ARC Pour la Recherche sur le Cancer (Equipe Labellisee)
- Laboratoire d'Excellence TouCan, Roche (imCORE)
Ask authors/readers for more resources
T cells responding to persistent tumor or viral antigens progressively lose their functional properties, a feature known as exhaustion. This state is also characterized by cell-surface expression of multiple inhibitory immune checkpoint receptors (IRs). Cancer immunotherapy by immune checkpoint targeting has shown impressive clinical outcomes, but requires substantial improvement given the limited number of patients who benefit from the treatment. Targeting the mechanisms controlling immune checkpoint expression could represent a step towards this aim. Accumulating data indicate that this strategy can limit immune checkpoint expression, in some instances simultaneously inhibiting several immune checkpoints. This review discusses various mechanisms through which IRs are activated or regulated, and ways these mechanisms could be exploited to develop more effective future immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available